Natural killer cells: A review of manufacturing and clinical utility

Transfusion

Volumn 53, Issue 2, 2013, Pages 404-410

  Koepsell, Scott A ^a   Miller, Jeffrey S ^a   McKenna, David H ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; CD56 ANTIGEN; CYCLIC GMP; CYTOKINE; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; OKT 3; STEM CELL FACTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APHERESIS; BIOREACTOR; BREAST CARCINOMA; CANCER IMMUNOTHERAPY; CELL FUNCTION; CELL MATURATION; CLINICAL TRIAL (TOPIC); COLON CARCINOMA; CYTOKINE PRODUCTION; HUMAN; IMMUNOMAGNETIC SEPARATION; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOMA; LYMPHOID TISSUE; MAJOR HISTOCOMPATIBILITY COMPLEX; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NEUROBLASTOMA; OVARY CARCINOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; REVIEW;

BLOOD BANKS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INDUSTRY; KILLER CELLS, NATURAL; UTILIZATION REVIEW;

EID: 84873460841     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2012.03724.x     Document Type: Review

References (44)

1. Timonen T, Ortaldo JR, Herberman RB,. Characteristics of human large granular lymphocytes and relationship to natural killer and K cells. J Exp Med 1981; 153: 569-82.
2. Lanier LL, Testi R, Bindl J, Phillips JH,. Identity of Leu-19 (CD56) leukocyte differentiation antigen and neural cell adhesion molecule. J Exp Med 1989; 169: 2233-8.
3. Reichert T, DeBruyère M, Deneys V, Tötterman T, Lydyard P, Yuksel F, Chapel H, Jewell D, Van Hove L, Linden J, Buchner L,. Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol 1991; 60: 190-208.
4. Ferlazzo G, Thomas D, Lin SL, Goodman K, Morandi B, Muller WA, Moretta A, Munz C,. The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol 2004; 172: 1455-62.
5. Trinchieri G, Valiante N,. Receptors for the Fc fragment of IgG on natural killer cells. Nat Immun 1993; 12: 218-34.
6. Kay HD, Fagnani R, Bonnard GD,. Cytotoxicity against the K562 erythroleukemia cell line by human natural killer (NK) cells which do not bear free Fc receptors for IgG. Int J Cancer 1979; 24: 141-50.
7. Stern P, Gidlund M, Orn A, Wigzell H,. Natural killer cells mediate lysis of embryonal carcinoma cells lacking MHC. Nature 1980; 285: 341-2.
8. Leiden JM, Gottesdiener KM, Quertermous T, Coury L, Bray RA, Gottschalk L, Gebel H, Seidman JG, Strominger JL, Landay AL,. T-cell receptor gene rearrangement and expression in human natural killer cells: natural killer activity is not dependent on the rearrangement and expression of T-cell receptor alpha, beta, or gamma genes. Immunogenetics 1988; 27: 231-8.
9. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, Yokoyama WM, Ugolini S,. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331: 44-9.
10. Brodin P, Karre K, Hoglund P,. NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol 2009; 30: 143-9.
11. Purdy AK, Campbell KS,. Natural killer cells and cancer: regulation by the killer cell Ig-like receptors (KIR). Cancer Biol Ther 2009; 8: 2211-20.
12. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, Posati S, Rogaia D, Frassoni F, Aversa F, Martelli MF, Velardi A,. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097-100.
13. Weisdorf D, Cooley S, Devine S, Fehninger T, Dipersio J, Anasetti C, Waller E, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J,. T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. Biol Blood Marrow Transplant 2012; 18: 937-43.
14. Sutlu T, Alici E,. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009; 266: 154-81.
15. Spanholtz J, Preijers F, Tordoir M, Trilsbeek C, Paardekooper J, de Witte T, Schaap N, Dolstra H,. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS ONE 2011; 6: e20740.
16. Parkhurst MR, Riley JP, Dudley ME, Rosenberg SA,. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011; 17: 6287-97.
17. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D,. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69: 4010-7.
18. Berg M, Lundqvist A, McCoy P Jr, Samsel L, Fan Y, Tawab A, Childs R,. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009; 11: 341-55.
19. Lundqvist A, Berg M, Smith A, Childs RW,. Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer Cells. J Cancer 2011; 2: 383-5.
20. Luhm J, Brand JM, Koritke P, Hoppner M, Kirchner H, Frohn C,. Large-scale generation of natural killer lymphocytes for clinical application. J Hematother Stem Cell Res 2002; 11: 651-7.
21. Tam YK, Martinson JA, Doligosa K, Klingemann HG,. Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy 2003; 5: 259-72.
22. Arai S, Meagher R, Swearingen M, Myint H, Rich E, Martinson J, Klingemann H,. Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial. Cytotherapy 2008; 10: 625-32.
23. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK, McKenna D, Le C, Defor TE, Burns LJ, Orchard PJ, Blazar BR, Wagner JE, Slungaard A, Weisdorf DJ, Okazaki IJ, McGlave PB,. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005; 105: 3051-7.
24. McKenna DH Jr, Sumstad D, Bostrom N, Kadidlo DM, Fautsch S, McNearney S, Dewaard R, McGlave PB, Weisdorf DJ, Wagner JE, McCullough J, Miller JS,. Good manufacturing practices production of natural killer cells for immunotherapy: a six-year single-institution experience. Transfusion 2007; 47: 520-8.
25. Rubnitz JE, Inaba H, Ribeiro RC, Pounds S, Rooney B, Bell T, Pui CH, Leung W,. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010; 28: 955-9.
26. Alici E, Sutlu T, Bjorkstrand B, Gilljam M, Stellan B, Nahi H, Quezada HC, Gahrton G, Ljunggren HG, Dilber MS,. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood 2008; 111: 3155-62.
27. Siegler U, Meyer-Monard S, Jorger S, Stern M, Tichelli A, Gratwohl A, Wodnar-Filipowicz A, Kalberer CP,. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy 2010; 12: 750-63.
28. Sutlu T, Stellan B, Gilljam M, Quezada HC, Nahi H, Gahrton G, Alici E,. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 2010; 12: 1044-55.
29. Klingemann HG, Martinson J,. Ex vivo expansion of natural killer cells for clinical applications. Cytotherapy 2004; 6: 15-22.
30. Iyengar R, Handgretinger R, Babarin-Dorner A, Leimig T, Otto M, Geiger TL, Holladay MS, Houston J, Leung W,. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 2003; 5: 479-84.
31. Blum KS, Pabst R,. Lymphocyte numbers and subsets in the human blood. Do they mirror the situation in all organs? Immunol Lett 2007; 108: 45-51.
32. Miller JS, Oelkers S, Verfaillie C, McGlave P,. Role of monocytes in the expansion of human activated natural killer cells. Blood 1992; 80: 2221-9.
33. Meyer-Monard S, Passweg J, Siegler U, Kalberer C, Koehl U, Rovo A, Halter J, Stern M, Heim D, Rischewski J, Gratwohl A, Tichelli A,. Clinical-grade purification of natural killer cells in haploidentical hematopoietic stem cell transplantation. Transfusion 2009; 49: 362-71.
34. Lundqvist A, Yokoyama H, Smith A, Berg M, Childs R,. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood 2009; 113: 6120-7.
35. Cooley S, Weisdorf DJ, Guethlein LA, Klein JP, Wang T, Le CT, Marsh SG, Geraghty D, Spellman S, Haagenson MD, Ladner M, Trachtenberg E, Parham P, Miller JS,. Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia. Blood 2010; 116: 2411-9.
36. Gong JH, Maki G, Klingemann HG,. Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells. Leukemia 1994; 8: 652-8.
37. Koepsell SA, Kadidlo DM, Fautsch S, McCullough J, Klingemann H, Wagner JE, Miller JS, McKenna DH Jr,. Successful "in-flight" activation of natural killer cells during long-distance shipping. Transfusion 2013; 53: 398-403.
38. Brehm C, Huenecke S, Quaiser A, Esser R, Bremm M, Kloess S, Soerensen J, Kreyenberg H, Seidl C, Becker PS, Muhl H, Klingebiel T, Bader P, Passweg JR, Schwabe D, Koehl U,. IL-2 stimulated but not unstimulated NK cells induce selective disappearance of peripheral blood cells: concomitant Results to a phase I/II study. PLoS ONE 2011; 6: e27351.
39. Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T,. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer. Clin Cancer Res 2006; 12: 6079-86.
40. Krause SW, Gastpar R, Andreesen R, Gross C, Ullrich H, Thonigs G, Pfister K, Multhoff G,. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res 2004; 10: 3699-707.
41. Yoon SR, Lee YS, Yang SH, Ahn KH, Lee JH, Kim DY, Kang YA, Jeon M, Seol M, Ryu SG, Chung JW, Choi I, Lee KH,. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant 2010; 45: 1038-46.
42. Barkholt L, Alici E, Conrad R, Sutlu T, Gilljam M, Stellan B, Christensson B, Guven H, Bjorkstrom NK, Soderdahl G, Cederlund K, Kimby E, Aschan J, Ringden O, Ljunggren HG, Dilber MS,. Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy 2009; 1: 753-64.
43. Curti A, Ruggeri L, D'Addio A, Bontadini A, Dan E, Motta MR, Trabanelli S, Giudice V, Urbani E, Martinelli G, Paolini S, Fruet F, Isidori A, Parisi S, Bandini G, Baccarani M, Velardi A, Lemoli RM,. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011; 118: 3273-9.
44. Geller MA, Cooley S, Judson PL, Ghebre R, Carson LF, Argenta PA, Jonson AL, Panoskaltsis-Mortari A, Curtsinger J, McKenna D, Dusenbery K, Bliss R, Downs LS, Miller JS,. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011; 13: 98-107.